Table 3. IMRT versus 2DCRT in subgroup analysis by tumor stage in multivariate analysis in the original unmatched cohort*.
| Subgroup | Overall survival | Locoregional relapse-free survival | Distant metastasis-free survival | |||
|---|---|---|---|---|---|---|
| Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | |
| T-stage | ||||||
| T1-2 | 1.24 (0.66-2.35) | 0.503 | 1.08 (0.58-2.02) | 0.802 | 1.95 (0.75-5.05) | 0.170 |
| T3-4 | 1.15 (0.70-1.90) | 0.574 | 1.78 (0.74-4.30) | 0.200 | 0.65 (0.36-1.16) | 0.146 |
| N-stage | ||||||
| N0-1 | 1.28 (0.80-2.03) | 0.302 | 1.26 (0.73-2.19) | 0.402 | 0.84 (0.48-1.48) | 0.543 |
| N2-3 | 1.03 (0.47-2.26) | 0.945 | 1.12 (0.31-4.07) | 0.869 | 1.06 (0.39-2.87) | 0.908 |
| Clinical stage | ||||||
| I+II | 1.43 (0.69-2.97) | 0.336 | 1.22 (0.63-2.38) | 0.559 | 1.49 (0.56-3.94) | 0.421 |
| III+IV | 1.13 (0.71-1.80) | 0.600 | 1.29 (0.60-2.78) | 0.521 | 0.72 (0.41-1.26) | 0.250 |
Abbreviations: IMRT = intensity-modulated radiotherapy, 2DCRT = two-dimensional conventional radiotherapy, CI = confidence interval
*
Adjusted for age (continuous), sex, histology, immunoglobulin A against viral capsid antigen (<80/80-320/≥320), immunoglobulin A against early antigen (<10/10-40/≥40), T-stage and N-stage by forward selection.